News Sentiment

QTTB sentiment intelligence

Q32 Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 29 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 11.21 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 21

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-14.4% over one week, -11.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Form 424B5 Q32 Bio Inc For: 15 July By Investing.com

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -14.4% Price reacting lower
Trend fit Trend active -11.3% over four weeks
Fair value -17.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 16
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 21
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingView 3
simplywall.st 3
Stock Titan 2
PR Newswire 2
StocksToTrade 2
marketscreener.com 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Earnings 13
Market update 11
Balance sheet 3
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-29 of 29
Stock Titan Direct company coverage

Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal

Q32 Bio (Nasdaq: QTTB) announced a public offering totaling $187.6 million, or up to $215.8 million if underwriters exercise their full option. The offering includes 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants for 4,931,506 shares at $18.2499 per

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 21:19
Source
Stock Titan
GuruFocus Direct company coverage

Q32 Bio (QTTB) Launches $200M Public Offering to Fund Clinical Development

Q32 Bio Inc (QTTB) announced a $200 million public offering, selling common stock and pre-funded warrants to fund clinical trials for bempikibart, a drug targeting autoimmune and inflammatory diseases. Despite a low GF Score of 17/100, the company exhibits strong financial health

Tone
Positive 61/100
Event
Market update
Published
15 Jul 2026 06:41
Source
GuruFocus
PR Newswire Direct company coverage

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. announced the pricing of a public offering expected to raise approximately $200 million. The offering includes shares of common stock at $18.25 per share and pre-funded warrants at $18.2499 per warrant, with an option for underwriters to purchase additional shares. T

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:40
Source
PR Newswire
PR Newswire Direct company coverage

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced a proposed underwritten public offering of $200 million in common stock and pre-funded warrants. The company also intends to grant underwriters a 30-day option to purchase an additional $30 million

Tone
Negative 26/100
Event
Market update
Published
13 Jul 2026 20:11
Source
PR Newswire
StocksToTrade Direct company coverage

QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet

Q32 Bio Inc. (QTTB) stock recently surged by 67.91% due to increased investor optimism and significant volatility. The company holds about $51 million in cash with low debt, providing a solid financial runway despite ongoing operating losses. This makes QTTB a playground for mome

Tone
Positive 72/100
Event
Balance sheet
Published
13 Jul 2026 10:02
Source
StocksToTrade
Investing.com Direct company coverage

Q32 Bio stock surges 60% on positive alopecia areata trial data

Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% after reporting positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe alopecia areata. The trial met its primary endpoint, showing a significant reduction in SALT

Tone
Positive 92/100
Event
Earnings
Published
13 Jul 2026 07:04
Source
Investing.com
Moomoo Direct company coverage

$Q32 Bio (QTTB.US)$ thank market left 30 %

A user on the moomoo Community platform posted a brief comment regarding Q32 Bio (QTTB.US), stating "thank market left 30 %." This post was made by user "Revi2020" and was part of a discussion about sharing profit/loss on the platform, indicating a significant drop in the stock's

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 04:10
Source
Moomoo
StocksToTrade Direct company coverage

Q32 Bio Inc. QTTB Extends Volatile Rally As Traders Eye Key Levels

Q32 Bio Inc. (QTTB) is experiencing a volatile uptrend, with its stock price increasing by 15.57% on July 12, 2026, driven by positive news and strong investor interest. Despite robust gross margins and liquidity, the company faces ongoing losses and dilution risks due to negativ

Tone
Positive 64/100
Event
Balance sheet
Published
12 Jul 2026 15:40
Source
StocksToTrade
www.timothysykes.com Direct company coverage

Q32 Bio Inc. QTTB Stock Jumps After Volatile Spike Draws Trader Focus

Q32 Bio Inc. (QTTB) stock is experiencing a volatile jump, trading up 15.57% due to investor optimism over pivotal autoimmune drug trial results. Despite strong gross margins and liquidity, the company faces significant losses and operating cash burn, making it a speculative stoc

Tone
Positive 61/100
Event
Balance sheet
Published
12 Jul 2026 11:08
Source
www.timothysykes.com
Market source Direct company coverage

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

Q32 Bio (Nasdaq: QTTB) is scheduled to announce 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe or very severe alopecia areata on Monday, July 13, 2026. Following the announcement, the clinical stage biotechnolo

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 20:10
Source
Market source
Stock Titan Direct company coverage

Q32 Bio Inc. (QTTB) gains Boxer Capital group as 13.3% shareholder

A group led by Boxer Capital Management, LLC has reported a 13.3% beneficial ownership stake in Q32 Bio Inc. (QTTB), amounting to 3,149,310 shares of common stock as of June 30, 2026. This ownership, held with shared voting and dispositive power, is considered a passive investmen

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 20:10
Source
Stock Titan
marketscreener.com Direct company coverage

Q32 Bio Inc.(NasdaqCM:QTTB) added to Russell Microcap Value Benchmark Index

Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Value Benchmark Index as of June 29, 2026. This addition indicates the company's growing recognition in the financial markets, following recent activities such as a mixed shelf filing and private placement fi

Tone
Positive 82/100
Event
Market update
Published
29 Jun 2026 16:11
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Growth Benchmark Index

Q32 Bio Inc. (NasdaqCM: QTTB) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company focuses on developing therapies for autoimmune and inflammatory diseases, with its lead candidate bempikibart (ADX-914) currently in a Phase 2 program for alopec

Tone
Positive 77/100
Event
Market update
Published
29 Jun 2026 13:11
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Index

Q32 Bio Inc. (NasdaqCM: QTTB) has been included in the Russell Microcap Index, a significant development for the clinical-stage biotechnology company. This inclusion follows its addition to the Russell Microcap Growth Benchmark Index and Russell 3000E Growth Benchmark Index. The

Tone
Positive 81/100
Event
Market update
Published
29 Jun 2026 06:11
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Value Benchmark

Q32 Bio Inc. (NasdaqCM: QTTB) has been added to several Russell indices, including the Russell 3000E Value Benchmark, Russell Microcap Value Benchmark, and Russell Microcap Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing therapies for aut

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 05:10
Source
www.marketscreener.com
TradingView Direct company coverage

Q32 Bio Inc Actuals & Estimates (MUN:DB0)

This article provides an overview of Q32 Bio Inc (DB0) stock, including financial actuals and estimates, analyst forecasts, and historical price data. It covers frequently asked questions regarding the stock ticker, future price predictions, historical highs and lows, earnings re

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:08
Source
TradingView
TradingView Direct company coverage

Q32 Bio Inc Actuals & Estimates (NASDAQ:QTTB)

This article provides an overview of Q32 Bio Inc. (NASDAQ: QTTB) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and analyst estimates, earnings reports, and future forecasts, while emphasizing that the cont

Tone
Positive 64/100
Event
Earnings
Published
26 Jun 2026 01:39
Source
TradingView